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Dominance of Nonmalignant T-Cell Clones and
Distortion of the TCR Repertoire in the Peripheral
Blood of Patients with Cutaneous CD30þ
Lymphoproliferative Disorders
Daniel Humme1, Ansgar Lukowsky1, Matthias Steinhoff1, Marc Beyer1, Peter Walden1, Wolfram Sterry1 and
Chalid Assaf1
The CD30-positive cutaneous lymphoproliferative disorders (CLPD) include lymphomatoid papulosis (LyP) and
primary cutaneous anaplastic large T-cell lymphoma (cALCL). Despite the malign-appearing histology, an
excellent prognosis and spontaneous regression of single lesions characterize LyP. Even after years of clinical
remission newly erupting lesions often harbor a T-cell clone identical to the initial one. This fact raises the
question whether the clonal T-cell population persists in the peripheral blood. Therefore we investigated
genomic DNA of 126 samples of lesional skin and peripheral blood from 31 patients with CLPD, obtained during
both active disease and clinical remission. We performed molecular genetic analysis by combining T-cell
receptor (TCR)-g PCR with the GeneScan technique and assessed the TCR repertoire in selected blood samples
by b-variable complementarity-determining region 3 (CDR3) spectratyping qualitatively and quantitatively. We
were able to detect a clonal T-cell population in 36/43 (84%) skin samples and in 35/83 (42%) blood samples.
Comparison of the compartments in each patient demonstrated different T-cell clones in skin and blood,
suggesting a reactive nature of the clonal T cells in the blood. Moreover, CDR3 spectratyping revealed a
restricted T-cell repertoire in the blood, suggesting T-cell stimulation by an unknown antigen.
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INTRODUCTION
Primary cutaneous T-cell lymphomas are a heterogeneous
group of neoplasms, originating from clonal T cells. Apart
from mycosis fungoides (Mf), primary cutaneous CD30þ
lymphoproliferations (CLPD) are the most common entities,
accounting for approximately 30% of all cutaneous T-cell
lymphomas. This group includes lymphomatoid papulosis
(LyP) and primary cutaneous anaplastic large T-cell lympho-
ma (cALCL), and represents a range of disease with variable
morphology, immunophenotype, and clinical behavior
(Macaulay, 1968; Willemze et al., 2005; Droc et al., 2007).
Macaulay (1968) first described LyP as a chronic disorder,
which is characterized by recurrent self-healing dome-
shaped papules often spreading over a period of months or
several years. The disease usually occurs in adults with a
median age of 45 years (male to female patient ratio: 1.5:1)
but may occur in children as well (Willemze et al., 2005).
The lesions typically involve the trunk and extremities and
may be in various stages of evolution. Patients with LyP have
a benign clinical course with a 10-year survival rate of nearly
100% (Vergier et al., 1898; Macaulay, 1968; Paulli et al.,
1995). However, due to an unknown reason, in 10–20% of
the patients LyP can precede, coexist with, or follow
malignant lymphomas, especially Mf, Hodgkin’s lymphoma
HL or ALCL (Kaudewitz et al., 1990; Davis et al., 1992).
cALCL occurs predominantly in elderly adults, whereas
occurrence in children is rare (Beljaards et al., 1993).
By using molecular biological techniques, for example,
T-cell receptor (TCR) gene rearrangement analysis, clonal
T cells could be identified in LyP (Weiss et al., 1986; Davis
et al., 1992; Steinhoff et al., 2002; Gellrich et al., 2004).
Previous studies have demonstrated that the identical T-cell
clone could be detected in separate skin lesions and in skin
biopsies taken at different time points (Chott et al., 1996;
Steinhoff et al., 2002). Even in lesions recurring after several
years of clinical remission the identical TCR gene rearrange-
ment as in the initial lesions could be detected (Chott et al.,
1996; Steinhoff et al., 2002). Moreover, identical clonal TCR
gene rearrangements were also found in associated lymphomas
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as Mf, ALCL, and Hodgkin’s lymphoma (Kaudewitz et al., 1990,
1991; Wood et al., 1995; Chott et al., 1996), suggesting that LyP
may be a precursor (Kaudewitz et al., 1990; Davis et al., 1992;
Wood et al., 1995; Chott et al., 1996).
The fact that patients with LyP experience a relapsing
course of their disease and additionally develop in 10–20%
associated lymphomas even after years of clinical remission
(Kaudewitz et al., 1991; Wood et al., 1995; Chott et al.,
1996) raises the question of persistence of long-lived clonal
T cells during the symptom-free period. Recently, Schultz
et al. (2005) reported the detection of identical TCR
rearrangements in skin and peripheral blood in 2/6 investi-
gated patients. Interestingly, in 1/6 patients the T-cell clone
could be detected in the peripheral blood during the
symptom-free period. In contrast Whittaker et al. (1991)
could not demonstrate a clonal T-cell population in the blood
in 7/8 cases. However, there is a lack of broad systemic
analyses to answer definitely the question whether the T-cell
clone in the skin lesions also occurs in the peripheral blood.
In this study we first investigated if an identical T-cell
clone in both skin and peripheral blood of a larger number of
patients can be detected. Further on we analyzed the TCR-b
repertoire qualitatively and quantitatively to determine
whether an association between TCR clonality and TCR
repertoire disturbances exists. To this end we analyzed and
compared clonal TCR-g rearrangements of 43 lesional skin
biopsies and 83 peripheral blood mononuclear cell (PBMC)
samples of 31 patients.
Skin and blood samples were taken and investigated at the
times of active disease. Additional blood samples were
investigated for clonality during the time of clinical remis-
sion. We applied the recently developed standardized
Biomed 2 protocol in combination with the GeneScan
analysis for TCR-g rearrangements (van Dongen et al.,
2003). Moreover, evaluation of the TCR repertoire of the
peripheral blood of patients with CLPD was performed on
mRNA level by T-cell spectratyping of the complementarity-
determining region 3 (CDR3).
RESULTS
Analytical sensitivity of the TCR-c Biomed 2 protocol
The analytical sensitivity of the TCR-g Biomed II PCR in
combination with the fluorescence fragment analysis techni-
que was determined by serial dilution of the T-cell line MyLa
in pooled PBMCs of 10 healthy donors. The PCR assays had
a detection threshold of 2–5% clonally rearranged DNA in
a polyclonal background (Figure 1).
Detection of a clonal T-cell population in skin lesions of CLPD
To determine the occurrence of a clonal T-cell population in
lesional skin of patients with LyP and cALCL (patient charac-
teristics are described in Table 1), we performed TCR-g
clonality analyses of genomic DNA of lesional T lymphocytes
(Table 2). A clonal T-cell population could be detected in
lesional skin biopsies of 17/21 (81%) patients (21/27 biopsies
(78%)) with LyP. In addition, multiple skin (2–3) specimens
were available from four patients (patients 8, 9, 15, 19). In
three of these patients an identical TCR gene rearrangement
could be detected over a period of up to 3 years
(representative example patient 9; Figure 2), demonstrating
the persistence of the skin T-cell clone in LyP. A monoclonal
T-cell expansion was detected in 6/7 (86%) patients with
cALCL (11/12 biopsies, 92%), and in all three investigated
cases with cutaneous manifestations of systemic anaplastic
large T-cell lymphoma (sALCL), that is, in 4/4 biopsies
(100%).
Detection of clonal T-cell population in the peripheral blood of
CLPD
The phenomenon of spontaneous regression and recurrence
of skin lesions observed in patients with LyP and cALCL raises
the question of persistence of the clonal T-cell population in
the peripheral blood. To determine clonality in the peripheral
blood we investigated genomic DNA of 83 blood specimens
for TCR-g gene rearrangements (Table 2). Of the 31 patients
29 had at least one skin lesion at the time when blood was
taken. The remaining two patients were in a state of clinical
remission. In the majority of the patients blood samples were
investigated during the clinical follow-up.
Clonal PCR products in PBMCs were detected in 8/21
(35%) patients with LyP (19/53 samples, 36%). In the other
patients a polyclonal distribution of the analyzed PBMCs was
found as exemplarily shown in Figure 3. Multiple (2–5) blood
specimens were available from 14 patients and 6 of these
patients demonstrated an identical clone in 2–4 separate
samples. In these patients an identical T-cell clone was
reproducibly detected over a period of at least 15 months as
shown for patient 9 (Figure 2). Patients 1–4, 10, 15, and 18 of
whom multiple blood samples were available consistently
showed a polyclonal distribution. From five patients blood
specimens were available during both active and inactive
phases of their disease. An identical clonal T-cell population
could be detected at both time points in three of these five
patients (60%).
In cases of ALCL, a clonal TCR gene rearrangement could
be detected in the peripheral blood in 6/7 patients (16/27
samples (59%) and in 0/3 patients with cALCL and sALCL,
respectively. The investigation of multiple blood specimens
was possible in 6/7 patients suffering from cALCL. Of the
seven patients four had an identical clone in separate blood
samples. In these patients the identical clone was demon-
strated over periods of 14 months to more than 3 years.
In all, we were able to demonstrate clonal T cells in the
skin samples of 26/31 (84%) patients with CLPD (17/21 (81%)
LyP, 6/7 (86%) cALCL, 3/3 (100%) sALCL).
Moreover, we were also able to detect clonality in the
peripheral blood in 14/31 (45%) patients diagnosed with
CLPD (8/21 (38%) LyP, 6/7 (86%) cALCL, 0/3 (0%) sALCL).
However, direct comparison of the clonal T-cell popula-
tion detected in the lesional skin and corresponding
PBMC sample of each patient by fluorescence fragment
analysis revealed a different rearrangement pattern in all
instances.
The different clonal T-cell populations detected in the skin
and corresponding blood samples could be followed up over
years within the same patient (exemplary in Figure 2; all cases
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demonstrated in Supplementary Data). As controls, corre-
sponding skin and blood samples of 10 patients with chronic
dermatitis were analyzed. In none of these samples a
monoclonal T-cell population was detected (data not shown).
Age distribution of patients with or without a clonal T-cell
population in the peripheral blood
In previous studies it has been clearly demonstrated that there
is a physiological age-related expansion of clonal T cells in
PBMCs, after the age of 65 years (Posnett et al., 1994; Schwab
et al., 1997; Muche et al., 2003; Vallejo, 2007). Therefore we
compared the average age of patients with clonal TCR-g and
a polyclonal distribution of the TCR-g gene rearrangement in
the peripheral blood, respectively.
For LyP patients showing polyclonal TCR-g distributions
had an average age of 38 years (range: 13–88 years, n¼ 13),
whereas patients who had a clonal TCR gene rearrangement
in the peripheral blood had an average age of 52 years
(range: 30–70 years, n¼8). In the six patients with cALCL
showing a clonal TCR-g gene rearrangement an average age
of 50 years (range: 23–77 years, n¼6) was calculated. The
one patient with cALCL who had a polyclonal distribution
of the TCR-g gene rearrangements in the PBMCs was 14 years
of age.
These data show that a clonal T-cell population in the
peripheral blood occurs much earlier in patients with
CLPD than physiologically expected for healthy elderly
individuals.
Restriction of the TCR repertoire in the peripheral blood of
patients with CLPD measured by CDR3 size analysis of TCR-b
chain transcripts
For further characterization of peripheral blood T cells of
patients with CLPD we looked for changes in the diversity of
the TCR repertoire. This was performed by CDR3 spectratyp-
ing, allowing visualization of the TCR repertoire as by the
TCR-b CDR3 distribution, on a single graph. In contrast to the
GeneScan technique the immunoscope analysis is performed
on the basis of mRNA. In this study the quantitative and
qualitative CDR3 distributions of the peripheral blood T cells
in 10 patients was analyzed (patients 1, 2, 5, 8, 12, 14, 15,
22, 23, 24). Patient 1 demonstrated an oligoclonal; patients 2,
5, 12, 14, 15, and 22 polyclonal; and patients 8, 23, and 24
monoclonal profile.
At the quantitative level, Vb family transcripts were found
accumulated in seven samples (Vb2 in the sample of patient 8
and, to a lesser extent, in patients 5, 14, and 15; Vb5.1 in
patients 14, 15, and 24; Vb6.1 in patient 1; Vb6.5 in patient
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Figure 1. Serial dilution of the clonal T-cell line MyLa in pooled PBMCs of 10 healthy donors. TCR-g PCR assays of tubes A (left side) and B (right side).
Dilution steps were performed at 100, 50, 25, 10, 5, 2, and 1% clonal cells, showing a sensitivity of 2–5% (MyLa cell line reveals a PCR product of 196 base pairs
in tube A and 182 base pairs in tube B); x axis, length of PCR products in base pairs (bp).
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5; Vb13.1 in patients 2, 5, 14, 15; and Vb17 in patient 24).
On the other hand, other Vb families (mainly the Vb13.5,
Vb15, Vb23, and Vb24 families) were only weakly repre-
sented in most of the samples.
At the qualitative level, an altered CDR3 length distribu-
tion profile in comparison to a Gaussian distribution was
observed for the majority of the Vb families in patients 1, 8
and to a lesser extent, in patients 22 and 23. In the other
samples most of the Vb families displayed a Gaussian length
distribution.
Comparison of the TCR-c gene rearrangement analyses and the
analyses of the CDR3 of TCR-b
The comparison of T-cell clonality and immunoscope
analysis for patient 8 with LyP who had developed an
associated lymphoma (Mf) presented a monoclonal TCR-g
rearrangement in the GeneScan and a very strong distortion
of the CDR3 distributions. In contrast, patient 1 with LyP
demonstrated an oligoclonal TCR-g rearrangement had a less
distorted CDR3 length distribution. Patient 15 with LyP
showed a polyclonal TCR rearrangement profile (GeneScan)
Table 1. Clinical characteristics of the patients with CD30+ lymphoproliferations
Patient dx Sex Age at dx
Extent of
skin lesion Treatment Course
Follow-up
month
Current
status
1 LyP, type A M 60 Multifocal Excision, local steroids, MTX SD 32 A w d
2 LyP, type A M 13 Multifocal PUVA, local steroid SD. 26 A w d
3 LyP, type A F 33 Localized Excision, local steroids SD 24 A w d
4 LyP, type A M 52 Multifocal Excision, MTX CR 168 A w d
5 LyP, type A F 31 Multifocal PUVA, MTX SD 73 A w d
6 LyP, type A M 40 Multifocal PUVA, systemic retinoids, MTX CR 96 A w/o d
7 LyP, type A F 38 Localized PUVA, excision SD 13 A w d
8 LyP, type A M 56 Localized Excision SD 55 A w d
9 LyP, type A M 64 Multifocal MTX, PUVA, local steroids SD 36 A w d
10 LyP, type A F 54 Solitary Excision, MTX CR 120 A w/o d
11 LyP, type A M 81 Multifocal Excision, radiation, chlorambucil, flucytoarabin PD 27 DOD
12 LyP, type A M 26 Multifocal Observation SD 12 A w d
13 LyP, type A M 26 Localized PUVA CR 33 A w/o d
14 LyP, type A F 24 Multifocal MTX CR 13 A w/o d
15 LyP, type A F 17 Multifocal Local steroids CR 39 A w/o d
16 LyP, type A F 58 Multifocal MTX SD 32 A w d
17 LyP, type A F 49 Multifocal PUVA, MTX, IFN-a SD 15 A w d
18 LyP, type A M 32 Multifocal MTX CR 55 A w/o d
19 LyP, type B M 73 localized excision, PUVA, MTX SD 33 A w d
20 LyP, type C M 52 Localized PUVA, excision, MTX SD 31 A w d
21 LyP, type C M 17 Localized Excision, PUVA, MTX CR 8 A w/o d
22 cALCL M 32 Solitary PUVA, radiation, excision, MTX CR 17 A w/o d
23 cALCL M 61 Solitary Excision, radiation, IFN-a, MTX, CHOP PD 44 A w d
24 cALCL F 51 Solitary Excision, MTX CR 45 A w/o d
25 cALCL M 16 Multifocal Excision, MTX SD 48 A w d
26 cALCL M 36 Localized Excision, radiation, vaccination, MTX, IFN-a PD 22 DOD
27 cALCL M 75 Solitary Excision, radiation SD 30 A w d
28 cALCL M 24 Solitary Excision, radiation CR 27 A w/o d
29 sALCL M 37 Localized CHOP, alemtuzumab PD 27 A w d
30 sALCL M 52 Localized CHOP, radiation, MTX, doxorubicin, vepisid PD 42 A w d
31 sALCL M 18 Localized BMT CR 66 A w/o d
Abbreviations: A w d, alive with disease; A w/o d, alive without disease; BMT, bone marrow transplantation; cALCL, cutaneous anaplastic large cell
lymphoma; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin (vincristin), prednisolone; CR, complete remission; DOD, died of disease; dx,
diagnosis; F, female; IFN-a, interferon-a; LyP, lymphomatoide Papulose; M, male; MTX, methotrexate; PD, progressive disease; PUVA, psoralene with UVA-
phototherapy; sALCL, systemic anaplastic large cell lymphoma; SD, stable disease.
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and a nearly Gaussian CDR3 length distribution in the
Immunoscope analyses of peripheral blood (Figure 4).
All in all, three of the four investigated blood samples
representing a clonal TCR-g rearrangement demonstrated a
clear distortion of the CDR3 distribution (patients 8, 23, 24).
Although demonstrating clonality in the peripheral blood,
patient 22 showed a nearly normal CDR3 length distribution.
All of the five patients 2, 5, 12, 14, and 15 with a polyclonal
TCR-g rearrangement had a balanced TCR-b repertoire.
Patient 1 with an oligoclonal profile in the GeneScan analysis
showed a distorted CDR3 distribution as previously des-
cribed.
Taken together, we were able to demonstrate a striking
association of the degree of clonality and the extent of CDR3
distortions found in the peripheral blood. Patients with a
polyclonal TCR gene rearrangement demonstrate a Gaussian-
like distribution of the TCR repertoire, patients with an
oligoclonal TCR gene rearrangement an altered, and patients
with a dominant T-cell clone a severely distorted TCR
repertoire.
Table 2. Patient and specimen information
Patient Entity
No. of cases with
clonality in skin
Total of
investigated
skin cases Size in bp (skin)
No. of cases with
clonality in
blood
Total of
investigated
blood cases Size in bp (blood)
1 LyP, type A 0 1 NA 0 (five oligo) 5 NA
2 LyP, type A 1 1 216, 252 (A) 0 5 NA
3 LyP, type A 1 1 114 (B) 0 3 NA
4 LyP, type A 0 1 NA 0 3 NA
5 LyP, type A 1 1 103 (B) 0 1 NA
6 LyP, type A 0 1 NA 2 5 155 (A)
7 LyP, type A 0 1 NA 1 2 107 (B)
8 LyP, type A 2 3 184,216 (A) 3 3 186 (B)
9 LyP, type A 3 3 145 (A) 3 3 159 (A) 112 (B)
10 LyP, type A 1 1 160,209 (A) 0 4 NA
11 LyP, type A 1 1 241 (A) 178 (B) 0 (one oligo) 1 NA
12 LyP, type A 1 1 218 (A) 184 (B) 0 1 NA
13 LyP, type A 1 1 177 (B) 4 4 174 (A)
14 LyP, type A 1 1 182 (B) 0 1 NA
15 LyP, type A 2 2 176 (A) 178 (B) 0 2 NA
16 LyP, type A 1 1 202,237 (A) 2 2 208 (B)
17 LyP, type A 1 1 215,229 (A) 1 1 150 (A)
18 LyP, type A 1 1 216,156 (A) 0 2 NA
19 LyP, type B 1 2 215 (A) 161 (B) 3 3 244 (A)
20 LyP, type C 1 1 216,219 (A) 0 1 NA
21 LyP, type C 1 1 154,236 (A) 0 1 NA
22 cALCL 0 1 NA 2 3 142 (B)
23 cALCL 3 3 157 (A) 2 5 152 (A)
24 cALCL 1 1 152,212 (A) 6 6 210,247 (A)
25 cALCL 1 1 215 (A) 180 (B) 0 1 NA
26 cALCL 2 2 155 (A) 194 (B) 1 5 218 (A) 110,117 (B)
27 cALCL 2 2 215 (A)1 4 4 243 (A) 157 (B) in 3/4
28 cALCL 2 2 151 (A) 1 3 159 (B)
29 sALCL 1 1 159 (A) 0 (one oligo) 1 NA
30 sALCL 2 2 173 (B) 0 (one oligo) 1 NA
31 sALCL 1 1 241 (A) 0 1 NA
Abbreviations: (A), rearrangement found in tube A; (B), rearrangement found in tube B; cALCL, cutaneous anaplastic large T-cell lymphoma; LyP,
lymphomatoid papulosis; Mf, mycosis fungoides; oligo, oligoclonal rearrangement; +1 add. peak, one additional peak was found; NA, not applicable;
sALCL, systemic ALCL.
1Identical clone in tube A (215 bp). Different clones in tube B, one at 100 bp the other at 161 bp.
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DISCUSSION
Macauley (1968) called LyP a ‘‘rhythmic paradoxical
eruption’’ and described it as a self-healing and usually
recurrent papular disorder. At present it is unclear, in which
compartments the clonal T cells persist during the relapse-
free period of LyP. One hypothesis is that the neoplastic cells
are disseminated in the peripheral blood and home back to
the skin to cause new lesions. To answer the question if the
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Figure 2. Comparison of clonal T-cell populations of lesional skin and peripheral blood of patient 9 (tube A). (Left side) Skin specimens were obtained in
01.1999 (a), 06.1999 (b), and 03.2002 (c) revealing an identical size of 145 bp. (Right side) Clonality of three separate blood specimens each with a fragment
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disease causing T-cell clone persists in the peripheral blood
in CLPD, we performed a systematic analysis of 126 lesional
skin and corresponding peripheral blood samples from
31 patients with special emphasis on LyP.
Our detection of a dominant T-cell clone in the skin of
81% of patients with LyP is in line with previous publications
showing a range of 45–83% (Weiss et al., 1986; Whittaker
et al., 1991; EI Azhary et al., 1994; Kadin, 2006). Our
comparably high detection rate underlines the sensitivity
of our approach. We also found a clonal T-cell population
in skin biopsies of 86% of the patients with cALCL. This is in
agreement with most studies showing a detectable T-cell
clone in nearly all cALCL (Willemze, 2005; Kadin, 2006). In
contrast to our findings, Greisser et al. (2006) detected
clonality in none of nine investigated LyP type A cases, but in
50% of Lyp type C (4/8). The discrepancies between the
published and our data reported in this study may be due to
the different protocols for the analysis of TCR rearrangements.
We used the sensitive Biomed primer sets which, according
to extensive comparative studies, produce an increased
detection rate of clonally expanded T cells in lymphomas
with low numbers of tumor cells such as LyP type A.
In the peripheral blood we found a clonal T-cell popu-
lation in 8/21 (38%) patients with LyP and in 6/7 (86%)
patients with cALCL. However, intraindividual comparison of
the clonal T-cell populations in blood and skin revealed
different TCR gene rearrangements in all cases. Thus, within
the sensitivity threshold of our technique of 2–5%, we were
not able to detect an identical T-cell clone in the skin and the
peripheral blood. So our results do not support the findings of
Schultz et al. (2005). They may have overrated the detection
of identical clones for the following two technical reasons.
First, they used a primer set covering only approximately
75% of the possible TCR-g gene rearrangements (McCarthy
et al., 1992). Second separation by PAGE, which only
distinguishes PCR products with length difference of at least
10 base pairs (Scheller et al., 1998) may wrongly give the
impression of identical clones.
In case of patients with sALCL we could not identify clonal
T-cell populations in the peripheral blood, which may be
mainly due to the limited number of cases investigated.
Earlier, clonality analyses had been performed for other
types of cutaneous T-cell lymphoma. (Muche et al., 2003)
detected identical TCR gene rearrangements in skin and
peripheral blood, indicating a dissemination of the malig-
nant T cells into the blood of patients with Mf. However,
analogous to our data, subsequent studies on a large number
of patients revealed distinct clonal proliferations in both
compartments in 48–73% of the patients (Delfau-Larue et al.,
1998; Muche et al., 2003). Moreover, clonal T-cell popula-
tions were detected in healthy individuals (5/38), in patients
with autoimmune dermatoses (3/8), with Mf (8/64) and with
cancer other than lymphoma (9/39) (Muche et al., 2003).
As the finding of a dominant T-cell clone in the peripheral
blood alone is not necessarily associated with a T-cell-
dependent disease, we performed an immunoscope analysis
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a monoclonal TCR-g rearrangement in the peripheral blood. Patient 1 (middle) with LyP demonstrated an oligoclonal TCR-g rearrangement in association with
an altered CDR3 length distribution whereas patient 15 (right side) with LyP presented a polyclonal GeneScan profile and a nearly Gaussian TCR-b CDR3 length
distribution in the peripheral blood.
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or CDR3 spectratyping of PBMCs. This technique provides
more insight into the TCR repertoire by analyzing all 24 Vb
families separately. As the CDR3 spectratyping is performed
on mRNA basis, quantitative aspects, for example, clonal
activation as well as qualitative aspects like repertoire distor-
tion, are taken into account. Our data from the immunoscope
analysis demonstrate that the detection of a clonal TCR
rearrangement in the peripheral blood is associated with a
strong distortion of the CDR3 distribution and the TCR
repertoire in most cases. In contrast, patients without a
detectable T-cell clone in the blood showed a normal TCR
repertoire. A pronounced overrepresentation of certain Vb
families at the quantitative level indicates a strong proli-
feration of subpopulations of T cells, maybe due to their
antitumor immune response (Albers et al., 2006). This
hypothesis is supported by data published within the past
years. For patients with Se´zary syndrome the expansion of
identical Vb families in the skin and the peripheral blood
were shown, representing identical T-cell clones (Ingen-
Housz-Oro et al., 2002). In addition to these dominant clones
further expanded, clones varying with time were observed in
the peripheral blood, suggesting nontumoral-reactive lym-
phocytes. Moreover, staining with CD 158k allowing to
differentiate between malignant (CD 158k -positive) and
nonmalignant (CD 158k -negative) T lymphocytes brought
additional evidence for expanded reactive T-cell clones in
patients with Se´zary syndrome (Ortonne et al., 2006).
In previous studies unrelated clonal T-cell proliferations in
the peripheral blood as well as alterations in the TCR
repertoire have been reported to occur frequently in patients
over the age of 65 years (Posnett et al., 1994; Schwab et al.,
1997; Muche et al., 2003; Vallejo, 2007). Vallejo (2007)
showed that the TCR diversity is usually maintained up to the
age of 65 years and rapidly diminishes thereafter. However,
patients from our study who demonstrated unrelated domi-
nant T-cell clones in the peripheral blood were much
younger than 65 years (average age 52 years) and all patients
with distorted CDR3 distributions were under the age of
65 years (51, 59, 60, and 61 years).
Interestingly, distortions of the immune repertoire were
also described in younger individuals suffering from chronic
diseases such as CMV infections, which suggest that
stimulation like persistent or periodic viral antigen spreading
may have comparable effects on the T-cell repertoire (Looney
et al., 1999; Koch et al., 2006). Restricted clonal dominance
has been reported from immunoscope analyses of other forms
of cutaneous lymphoma (Yawalkar et al., 2003) and other
cancers (Albers et al., 2006) and interpreted by the authors as
indicating contraction of the T-cell repertoires with sub-
stantial loss of TCR diversity. However, evaluating the
clonality and immunoscope data in the context of the
experiments assessing the sensitivity of the PCR-based
analyses of TCR repertoires suggests an alternative interpreta-
tion. Already 10% monoclonal T cells admixed to a
polyclonal T-cell population produce a clonality scan profile
that mimics single clonal dominance in the test sample
although still 90% of the cells are polyclonal. As in the
immunoscope analyses the 24 TCR Vb families are scanned
separately, the sensitivity of detection of clonal dominance is
here considerably enhanced. In addition, the qualitative Vb
distribution is similar to the findings of van den Beemd et al.
(2000) in healthy individuals. Taken together, the earlier
reports and our findings raise the possibility that the
distortions of TCR repertoires and prominence of nonmalig-
nant or else disease-associated T-cell clones in patients with
CLPD may be related to chronic stimulation of the T cells by
unknown antigens possibly associated with the CLPD.
In conclusion, we investigated clonal T-cell proliferations
in the skin and the peripheral blood of 31 patients with CLPD.
In addition, a clonal TCR rearrangement in a high percentage
of skin samples our data demonstrate a different T-cell clone
in the blood in 35 and 86% of patients with LyP and ALCL,
respectively. Immunoscope analysis produced evidence that
the clonal expansions detected in the peripheral blood are
associated with an altered CDR3 length distribution pattern,
which also occurred at a younger age and more frequently
in patients with CLPD compared to reports for healthy
individuals. We suggest that the unexpectedly high detection
rate of clonality in the peripheral blood of patients with LyP
might be due to a cancer-specific antigen-dependent T-cell
proliferation. However, the exact nature of the skin-unrelated
clonal T-cell proliferation in the blood remains to be
resolved.
MATERIALS AND METHODS
Patients
The study included the analyses of genomic DNA from a total of 126
samples consisting of 83 blood and 43 skin samples from 31
clinically well-characterized patients with CD30þ lymphoprolifera-
tions. All patients were treated and followed up by the Department
of Dermatology, Charite´, Berlin. This group consisted of 21 patients
with LyP, 7 patients with cALCL, and 3 patients presenting with a
secondary skin manifestation of sALCL. Detailed clinical information
on all patients is summarized in Table 1. As a control skin and blood
samples were investigated from 10 patients with chronic dermatitis.
According to the recent World Health Organization–European
Organization for Research and Treatment of Cancer classification
LyP was defined as recurrent nodular eruptions with evidence of
spontaneous regression of skin lesions and histological features
consistent with LyP. cALCL was defined as nodules or tumor lesions
with histological features for cALCL and no evidence of extra-
cutaneous manifestation at initial presentation (Willemze et al.,
2005).
The research committee of the Charite´ Universita¨tsmedizin Berlin
has approved the described studies. Informed consent for the
experimental studies was obtained from the patients. The study
was conducted according to the Declaration of Helsinki Principles.
Characterization of specimens
All skin samples were examined by hematoxylin eosin staining and
immunohistological staining (CD4, 1F6; Novocastra, Newcastle
upon Tyne, UK; CD3, polyclonal CD3, CD8 (C8-144), CD45RO
(OPD4), CD30 (Ber-H2), ALK (Dako, Glostrup, Denmark). To
unmask the antigenic epitopes, the sections by high-pressure
cooking in 10mM citrate buffer (pH 6.0). According to the amount
of CD30þ atypical cells, LyP cases were subdivided into three
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histological types designated as A with scattered CD30þ cells, B
with absence of CD30þ cells, and C with sheets of CD30þ cells.
DNA preparation
For extraction of genomic DNA, 10 paraffin sections per sample
(each 10mm) were dissolved twice in 1ml roticlear, centrifuged at
13,200 r.p.m. for 5 minutes and washed twice with ethanol followed
by centrifugation as described earlier. To achieve a complete
elimination of ethanol the specimens were dried in a dissicater.
Extraction buffer (200ml) and proteinase K (20 ml) (concentration
2.5mgml1, QIAamp DNA Kit; Qiagen; Hilden, Germany) were
added and incubated overnight at 55 1C followed by 20 minutes at
95 1C and centrifugation at 13,200 r.p.m. for 10 minutes.
Genomic DNA from blood containing about 1 106 PBMCs was
used. PBMCs were prepared from 10ml heparinized blood per
sample using Ficoll-HyPaque (Pharmacia, Freiburg, Germany). The
DNA extraction was performed according to a standard procedure
(Sambrook et al., 1989). Genomic DNA from the MyLa cell line was
extracted with a DNA purification kit (Blood DNA Purification Midi
Kit; Qiagen) according to the manufacturer’s instructions using the
midi spin protocol for whole blood. The DNA concentrations were
measured by absorbance at 260 nm.
TCR-c PCR and fluorescent fragment analysis
TCR-g rearrangements were amplified by PCR according to the
standardized Biomed 2 protocol (van Dongen et al., 2003). The cell
lines MyLa and SeAx served as positive controls. Samples without
DNA were used as negative controls in each assay. To confirm a
successful amplification, 8ml of each PCR product was screened on
a 2% ethidium bromide-stained agarose gel for the detection of
clonal bands or polyclonal smears.
For GeneScan analyses Jap1/2 and Jg1/2 Biomed 2 primers were
fluorescence-labeled and used for PCR as described in the Biomed 2
protocol (van Dongen et al., 2003). Fluorescence-labeled PCR
amplificate (1ml of each) was added to a mixture of 12.5 ml
deionized formamide and 0.5 ml GeneScan 500TM Rox internal
lane standard (PE Applied Biosystem, Weiterstadt, Germany). To
produce single-stranded DNA, the amplificates were denatured at
95 1C for 5 minutes and chilled on ice. Following this procedure, the
products were applied for GeneScan analyses to the ABI 310 PRISM
CE sequencer (PE Applied Biosystem). Each run was performed
under the following conditions: 60 1C, 15 kV, injection time of 5
seconds, separation time of 36 minutes, POP 6-filled 47-cm long
capillary (PE Applied Biosystem). The data from each run were
analyzed using the GeneScan 372 software (PE Applied Biosystem)
Lukowsky et al., 2003).
Determination of the sensitivity of the GeneScan analyses
The evaluation of the sensitivity of the GeneScan analyses was
performed by serial dilution of DNA from a monoclonal T-cell line
with DNA of polyclonal PBMCs. The polyclonal PCR products were
generated from PBMCs of 10 healthy individuals. DNA was prepared
with a DNA purification kit (Blood DNA Purification Midi Kit;
Qiagen) and analyzed as above. For serial dilution, DNA of the
MyLa cell line was mixed with the PBMC DNA at 50, 25, 10, 5, 2,
and 1%. DNA (5ml) with 50 ng DNA per ml was used per PCR for
fluorescence fragment analysis. Two independent assays were
performed per DNA ratio.
CDR3 size spectratyping (immunoscope)
The CDR3 size spectratyping was performed by TcLand (Nantes,
France) as described elsewhere (Pannetier et al., 1993).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGMENTS
We thank Sarina Richter and Linda El-Ahmad for their outstanding technical
assistance.
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Figure S1A. GeneScan images from skin and blood of patients 1–10.
Figure S1B. GeneScan images from skin and blood of patients 11–20.
Figure S1C. GeneScan images from skin and blood of patients 21–31.
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